Olgu ERKİN ÇINAR, Salih AKSU, Yahya BÜYÜKAŞIK, Nesrin Damla EYÜPOĞLU, Nilgün SAYINALP, Haluk DEMİROĞLU, Hakan GÖKER, Osman İlhami ÖZCEBE, İbrahim C. HAZNEDAROĞLU

Event-free Survival in Patients with Chronic Myeloid Leukemia Receiving Front-line Imatinib Mesylate

Objective: Chronic myeloid leukemia (CML) prognostication at the time of diagnosis is critical to determine the intensity of initial treatment. Event-free survival (EFS) has become a prominent concept of prognosis in the patients with chronic phase CML (CML-CP). The aim of this study is to assess the prognostic impact of bone marrow (BM) and peripheral blood (PB) cellular components, in correlation with the clinical parameters. Materials and Methods: One hundred forty-three patients with CMLCP on the front-line imatinib mesylate therapy were recruited into this study. Clinical and laboratory characteristics, therapeutic responses were recorded. Sokal, Euro/Hasford, The EUropean Treatment Outcome Study (EUTOS) and The EUTOS long-term survival (ELTS) scores were calculated for the studied patients. Results: Median follow-up time was 84 (IQR: 54-125) and median frontline therapeutic duration was 56 (IQR:23-89) months. Five-year EFS rate was 62.3% (95% CI: 53.9-70.7). The blast percentage in the BM, EUTOS scores, and basophil percentage in PB were related with the poor therapeutic outcomes in frontline therapy (p=0.002, p=0.002 and p=0.042, respectively). Although Sokal risk classification showed that the intermediate class had a higher event risk compared to the lowrisk class (p=0.001), the predictive association disappeared in high-risk classes. Conclusion: EUTOS score system has better predictive capability for front-line imatinib therapy comparing with other indices. Higher blast percentage in BM and increased basophil percentage in PB are independent risk factors, adversely related with EFS in patients with CML.

PDF

___

[1] Zackova D, Klamova H, Belohlavkova P, Stejskal L, Necasova T, Semerad L, et al. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. Leuk Lymphoma. 2021;62(1):194-202.
[2] Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376(10):917-27.
[3] Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-84.
[4] Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in” good-risk” chronic granulocytic leukemia. 1984.
[5] Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group. JNCI: Journal of the National Cancer Institute. 1998;90(11):850- 9.
[6] Uz B, Buyukasik Y, Atay H, Kelkitli E, Turgut M, Bektas O, et al. EUTOS CML prognostic scoring system predicts ELNbased ‘event-free survival’ better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology. 2013;18(5):247-52.
[7] Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with c hronic myeloid leukemia. Leukemia. 2016;30(1):48-56.
[8] Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood, The Journal of the American Society of Hematology. 2011;118(3):686-92.
[9] Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-84.
[10] Huang J, Zhao X. [Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016;41(8):809-14.
[11] Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, et al. The EUTOS long term survival score predicts disease specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice based cohort. Cancer Medicine. 2020;9(23):8931-9.
[12] Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29(9):1823.
[13] Yahng S-A, Jang E-J, Choi S-Y, Lee S-E, Kim S-H, Kim D-W. Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population. International journal of hematology. 2014;100(2):132-40.
[14] Elbedewy TA, Elashtokhy HEA. The Utility and Applicability of Chronic Myeloid Leukemia Scoring Systems for Predicting the Prognosis of Egyptian Patients on Imatinib: Retrospective Study. Journal of Leukemia. 2016:1-9.
[15] Iriyama N, Hatta Y, Kobayashi S, Uchino Y, Miura K, Kurita D, et al. The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia. International journal of hematology. 2014;100(4):379-85.
[16] Jabbour E, Cortes J, Nazha A, O’Brien S, Quintas-Cardama A, Pierce S, et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood, The Journal of the American Society of Hematology. 2012;119(19):4524-6.
[17] Marin D, Ibrahim AR, Goldman JM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(29):3944-5.
[18] Braga GW, Chauffaille ML, Moncau JE, Souto EX, Silva MR, Kerbauy J. Chronic myeloid leukemia (CML): prognostic factors and survival analysis. Sao Paulo Med J. 1996;114(1):1083-90.
[19] Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. 1985.
[20] Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood. 1982;60(6):1298-304.
[21] Jootar S, Ungkanont A, Chuncharunee S, Atichartakarn V. Multivariate analysis of prognostic factors in Philadelphia chromosome positive chronic myeloid leukemia: an update of the first series in Thailand. Asian Pac J Allergy Immunol. 1996;14(1):25-30.
[22] Chikkodi SV, Malhotra P, Naseem S, Khadwal A, Prakash G, Sahu KK, et al. Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2015;15 Suppl:S114-9.
[23] Valent P, Horny HP, Arock M. The underestimated role of basophils in Ph(+) chronic myeloid leukaemia. Eur J Clin Invest. 2018;48(10):e13000.
[24] Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla- Ibarz J, et al. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013;27(4):907-13.
[25] Kantarjian HM, Talpaz M, O’Brien S, Smith TL, Giles FJ, Faderl S, et al. Imatinib mesylate for Philadelphia chromosomepositive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002;8(7):2177-87.
[26] Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-9.
[27] Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-70.
[28] Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841- 51.
[29] Haznedaroglu IC, Kuzu I, Ilhan O. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors. Turk J Haematol. 2020;37(1):42-7.